Chimpanzee Adenovirus Vector Ebola Vaccine
Top Cited Papers
- 9 March 2017
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (10), 928-938
- https://doi.org/10.1056/nejmoa1410863
Abstract
The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international response to accelerate the availability of a preventive vaccine. A replication-defective recombinant chimpanzee adenovirus type 3–vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and Sudan species, that offers protection in the nonhuman primate model, was rapidly advanced into phase 1 clinical evaluation.Keywords
This publication has 25 references indexed in Scilit:
- Emergence of Zaire Ebola Virus Disease in GuineaNew England Journal of Medicine, 2014
- Ebola virus vaccines: an overview of current approachesExpert Review of Vaccines, 2014
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsVaccine, 2010
- Immunopathology of highly virulent pathogens: insights from Ebola virusNature Immunology, 2007
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006
- Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPsPLoS Medicine, 2006
- Ebola Virus Pathogenesis: Implications for Vaccines and TherapiesJournal of Virology, 2003
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003
- Development of a preventive vaccine for Ebola virus infection in primatesNature, 2000
- A system for functional analysis of Ebola virus glycoproteinProceedings of the National Academy of Sciences, 1997